Drug Trial Radar · NCT02149108
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
Last checked: Nov 20, 2026Latest source record: Jul 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
768
Actual
Start
Sep 25, 2014
Primary completion
May 13, 2016
Study completion Aug 25, 2016
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- May 29, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this Phase III study is to evaluate the efficacy of nintedanib in patients with metastatic colorectal cancer (mCRC) after failure of previous treatment with standard chemotherapy and biological agents.
Conditions
- Colorectal Neoplasms
Interventions
Nintedanib (BIBF 1120)Drug
PlaceboDrug
BSCDrug
BSCDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) by Central Review AssessmentTime frame: From randomisation until cut-off date 14JUN2016.
- Overall Survival (OS)Time frame: From randomisation until cut-off date 14JUN2016.
Locations
129 sites in 25 countries. Site status is shown where the registry gives one.
1199.52.0108 Boehringer Ingelheim Investigational Site
Los Angeles, California
1199.52.0105 Boehringer Ingelheim Investigational Site
New Haven, Connecticut
1199.52.0101 Boehringer Ingelheim Investigational Site
Plainville, Connecticut
1199.52.0121 Boehringer Ingelheim Investigational Site
Arlington Heights, Illinois
1199.52.0123 Boehringer Ingelheim Investigational Site
Sioux City, Iowa
1199.52.0104 Boehringer Ingelheim Investigational Site
Topeka, Kansas
1199.52.0114 Boehringer Ingelheim Investigational Site
New Orleans, Louisiana
1199.52.0113 Boehringer Ingelheim Investigational Site
Detroit, Michigan
1199.52.0125 Boehringer Ingelheim Investigational Site
Omaha, Nebraska
1199.52.0119 Boehringer Ingelheim Investigational Site
Johnson City, New York
1199.52.0115 Boehringer Ingelheim Investigational Site
Canton, Ohio
1199.52.0106 Boehringer Ingelheim Investigational Site
Sylvania, Ohio
1199.52.0102 Boehringer Ingelheim Investigational Site
Nashville, Tennessee
1199.52.0120 Boehringer Ingelheim Investigational Site
Fort Worth, Texas
1199.52.5404 Boehringer Ingelheim Investigational Site
Cdad. de Córdoba, Argentina
1199.52.5405 Boehringer Ingelheim Investigational Site
Cdad. de Córdoba, Argentina
1199.52.5401 Boehringer Ingelheim Investigational Site
Ciudad Autónoma de Bs As, Argentina
1199.52.5403 Boehringer Ingelheim Investigational Site
Ciudad Autónoma de Bs As, Argentina
1199.52.5406 Boehringer Ingelheim Investigational Site
Ciudad Autónoma de Bs As, Argentina
1199.52.6102 Boehringer Ingelheim Investigational Site
Concord, New South Wales, Australia
1199.52.6103 Boehringer Ingelheim Investigational Site
St Leonards, New South Wales, Australia
1199.52.6101 Boehringer Ingelheim Investigational Site
Wollongong, New South Wales, Australia
1199.52.6104 Boehringer Ingelheim Investigational Site
Heidelberg, Victoria, Australia
1199.52.6105 Boehringer Ingelheim Investigational Site
Nedlands, Western Australia, Australia
1199.52.6106 Boehringer Ingelheim Investigational Site
Perth, Western Australia, Australia
1199.52.4302 Boehringer Ingelheim Investigational Site
Linz, Austria
1199.52.4303 Boehringer Ingelheim Investigational Site
Vienna, Austria
1199.52.4304 Boehringer Ingelheim Investigational Site
Vienna, Austria
1199.52.3208 Boehringer Ingelheim Investigational Site
Aalst, Belgium
1199.52.3205 Boehringer Ingelheim Investigational Site
Bonheiden, Belgium
1199.52.3202 Boehringer Ingelheim Investigational Site
Brussels, Belgium
1199.52.3207 Boehringer Ingelheim Investigational Site
Charleroi, Belgium
1199.52.3204 Boehringer Ingelheim Investigational Site
Edegem, Belgium
1199.52.3203 Boehringer Ingelheim Investigational Site
Haine-Saint-Paul, Belgium
1199.52.3201 Boehringer Ingelheim Investigational Site
Leuven, Belgium
1199.52.3206 Boehringer Ingelheim Investigational Site
Liège, Belgium
1199.52.3521 Boehringer Ingelheim Investigational Site
Luxembourg, Belgium
1199.52.1003 Boehringer Ingelheim Investigational Site
Vancouver, British Columbia, Canada
1199.52.1004 Boehringer Ingelheim Investigational Site
Edmonton, Ontario, Canada
1199.52.1001 Boehringer Ingelheim Investigational Site
Toronto, Ontario, Canada
Showing 40 of 129 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.